GoAI
Get started
Capricor Therapeutics, Inc. logo

Capricor Therapeutics, Inc.

CAPR

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$6.29

−$0.545 · -7.97%

Aug 21, 4:00 PM ET

CAPR company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

30

Expensive

Momentum

36

Weakening

Sentiment

69

Bullish

Risk resilience

41

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Linda Marbán
Listed since
Feb 13, 2007
Employees
231

Market position

Day range

Current $6.29

52-week range

Current $6.29

Open
$6.80
Previous close
$6.835
Volume
8.36M
2.23× average
Average volume
3.74M
Average daily volume
Market cap
361.74M USD
Beta
0.53
Market reference 1
50-day average
$16.309
-61.43% below average
200-day average
$23.2036
-72.89% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.07B USD
P/E (TTM)
-2.57×
P/B (TTM)
1.48×
P/S (TTM)
0×
EV / EBITDA
-10.7×
Earnings yield
-7.83%
Free cash flow yield
-5.42%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-34.35%
Return on assets
-29.51%
Return on invested capital
-33.40%

Financial health

Debt / equity
0.37×
Current ratio
9.01×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends965%-2495%-5955%-9415%Gross margin, FY2021: 100.00%Gross margin, FY2022: -755.07%Gross margin, FY2023: -44.76%Gross margin, FY2024: -124.37%Operating margin, FY2021: -8549.86%Operating margin, FY2022: -1163.93%Operating margin, FY2023: -95.63%Operating margin, FY2024: -191.13%Net margin, FY2021: -8175.86%Net margin, FY2022: -1137.37%Net margin, FY2023: -88.52%Net margin, FY2024: -181.71%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 -755.07%. Gross margin FY2023 -44.76%. Gross margin FY2024 -124.37%. Operating margin FY2021 -8549.86%. Operating margin FY2022 -1163.93%. Operating margin FY2023 -95.63%. Operating margin FY2024 -191.13%. Net margin FY2021 -8175.86%. Net margin FY2022 -1137.37%. Net margin FY2023 -88.52%. Net margin FY2024 -181.71%.

Income trends

Revenue

22.27M USD-11.55%

Operating income

−108.14M USD-154.06%

Net income

−105.04M USD-159.58%
Income trends across reported periods38.51M USD−14.82M USD−68.15M USD−121.47M USDRevenue, FY2021: 244.9K USDRevenue, FY2022: 2.55M USDRevenue, FY2023: 25.18M USDRevenue, FY2024: 22.27M USDOperating income, FY2021: −20.94M USDOperating income, FY2022: −29.7M USDOperating income, FY2023: −24.08M USDOperating income, FY2024: −42.56M USDOperating income, FY2025: −108.14M USDNet income, FY2021: −20.02M USDNet income, FY2022: −29.02M USDNet income, FY2023: −22.29M USDNet income, FY2024: −40.47M USDNet income, FY2025: −105.04M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 244.9K USD. Revenue FY2022 2.55M USD. Revenue FY2023 25.18M USD. Revenue FY2024 22.27M USD. Operating income FY2021 −20.94M USD. Operating income FY2022 −29.7M USD. Operating income FY2023 −24.08M USD. Operating income FY2024 −42.56M USD. Operating income FY2025 −108.14M USD. Net income FY2021 −20.02M USD. Net income FY2022 −29.02M USD. Net income FY2023 −22.29M USD. Net income FY2024 −40.47M USD. Net income FY2025 −105.04M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue—22.27M USD25.18M USD2.55M USD244.9K USD
Cost of goods sold—49.97M USD36.45M USD21.82M USD—
Gross profit—−27.7M USD−11.27M USD−19.27M USD244.9K USD
Research and development84.45M USD49.97M USD36.45M USD21.82M USD13.57M USD
Selling, general, and administrative22.75M USD14.87M USD12.81M USD10.43M USD7.61M USD
Operating expenses108.14M USD14.87M USD12.81M USD10.43M USD21.18M USD
Interest income6.26M USD2.2M USD1.73M USD521.53K USD—
Interest expense3.05M USD————
Depreciation and amortization1.89M USD1.43M USD1.07M USD533.13K USD245.7K USD
Operating income−108.14M USD−42.56M USD−24.08M USD−29.7M USD−20.94M USD
Net income−105.04M USD−40.47M USD−22.29M USD−29.02M USD−20.02M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
27%
3 beats, 7 misses, 1 met estimate
Average EPS surprise
-16.86%
11 comparable reports
Latest EPS result
-0.7
Estimate -0.59 · Miss by 18.87%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.1-0.32-0.53-0.75Q1 '25BeatQ2 '25MissQ3 '25MissQ4 '25MetQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 19, 2025: actual -0.16, estimate -0.31, surprise +48.39%, Beat. Q2 2025, reported May 13, 2025: actual -0.53, estimate -0.33, surprise -60.61%, Miss. Q3 2025, reported Aug 11, 2025: actual -0.57, estimate -0.48, surprise -18.75%, Miss. Q4 2025, reported Nov 10, 2025: actual -0.54, estimate -0.54, surprise 0.00%, Met estimate. Q1 2026, reported Mar 12, 2026: actual -0.62, estimate -0.51, surprise -21.57%, Miss. Q2 2026, reported May 12, 2026: actual -0.59, estimate -0.55, surprise -7.27%, Miss. Q3 2026, reported Aug 14, 2026: actual -0.7, estimate -0.589, surprise -18.87%, Miss. Q4 2026, reported Nov 9, 2026: actual —, estimate -0.118, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates45.01M30.14M15.28M408KQ1 '25BeatQ2 '25EstimateQ3 '25EstimateQ4 '25EstimateQ1 '26EstimateQ2 '26EstimateQ3 '26EstimateQ4 '26Estimate
Q1 2025, reported Mar 19, 2025: actual 11.13M USD, estimate 5.5M USD, surprise +102.37%, Beat. Q2 2025, reported May 13, 2025: actual —, estimate 3.16M USD, surprise —, Comparison unavailable. Q3 2025, reported Aug 11, 2025: actual —, estimate 480K USD, surprise —, Comparison unavailable. Q4 2025, reported Nov 10, 2025: actual —, estimate 600K USD, surprise —, Comparison unavailable. Q1 2026, reported Mar 12, 2026: actual —, estimate 525K USD, surprise —, Comparison unavailable. Q2 2026, reported May 12, 2026: actual —, estimate 40M USD, surprise —, Comparison unavailable. Q3 2026, reported Aug 14, 2026: actual —, estimate 2.08M USD, surprise —, Comparison unavailable. Q4 2026, reported Nov 9, 2026: actual —, estimate 41.71M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

10 ratings
Strong buy00%
Buy770%
Hold330%
Sell00%
Strong sell00%

Recent analyst actions

9 institutions
Maxim GroupmaintainBuy

CAPR news

globenewswire.com

Bronstein, Gewirtz & Grossman LLC Urges Capricor Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for Capricor (CAPR) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 9/28/2026

Read source
newsfilecorp.com

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPR

New York, New York--(Newsfile Corp. - August 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025…

Read source
newsfilecorp.com

CAPR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 29, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Capricor To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in…

Read source
feeds.newsfilecorp.com

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPR

New York, New York--(Newsfile Corp. - August 22, 2026) - WHY: Rosen Law Firm, a global investor rights law firm,

Read source
globenewswire.com

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPR

NEW YORK, Aug. 22, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26,…

Read source
gurufocus.com

Capricor Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Capricor Therapeutics, Inc. - CAPR

Capricor Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Act

Read source

Corporate actions

Corporate action history

Stock split

Effective Jun 5, 2019

1:10

Stock split

Effective Nov 21, 2013

1:50

Stock split

Effective Feb 13, 2007

1:10

CAPR peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding CAPR

Funds reporting this stock among their holdings, ordered by reported position size.

State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
15.58M
Weight
0.14%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
9.43M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
6.37M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Fidelity Enhanced Small Cap ETF logoFidelity Enhanced Small Cap ETFFESM
Market value
3.88M
Weight
0.06%
AUM
6.03B USD
Expense ratio
0.28%
Price / 1D
$47.94+0.80%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
3.39M
Weight
0.02%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
2.28M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
Vanguard U.S. Momentum Factor ETF logoVanguard U.S. Momentum Factor ETFVFMO
Market value
2.05M
Weight
0.10%
AUM
1.8B USD
Expense ratio
0.13%
Price / 1D
$232.52+0.68%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
1.16M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%

Continue in GoAI

Research CAPR

research.disclaimer